Article

August 17, 2012

Survey: Few ACOs Ready For Financial Risk

Few hospitals interested in becoming accountable care organizations are ready to take on financial risk, according to a survey released Friday from The Commonwealth Fund.

“We’re really still at the very beginning of the adoption curve of the ACO model,” says lead author Anne-Marie Audet, who researches health system quality and efficiency at Commonwealth. “The challenge is that hospitals are still not ready to assume financial risk.”

Read the full story: http://tinyurl.com/8g89z59

Source: Kaiser Health News

Related Videos

Eboni Price-Haywood, MD, and Toni Flowers, PhD

Tom Belmon, CAP, GPBCH

CK Wang, MD, COTA

John Barkett, MBA

1 expert in this video

1 expert in this video

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center

Related Content

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Managed Care Cast

May 9th 2025

Frameworks for Advancing Health Equity: Food as Medicine

Giuliana Grossi Colleen Ereditario, MPH, RD, LDN

Learn about how Allegheny Health Network's "Food as Medicine" initiative tackles food insecurity and enhances health through personalized nutrition support.

Obesity highlighted on page | Image credit: Feng Yu – stock.adobe.com

May 16th 2025

5 Ways the US Obesity Landscape Strays From the Global Picture

Hayden E. Klein

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial saturation, access, and long-term care distinct from other parts of the world.

$Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com$

May 16th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Courtney Flaherty

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Related Content

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Managed Care Cast

May 9th 2025

Frameworks for Advancing Health Equity: Food as Medicine

Giuliana Grossi Colleen Ereditario, MPH, RD, LDN

Learn about how Allegheny Health Network's "Food as Medicine" initiative tackles food insecurity and enhances health through personalized nutrition support.

Obesity highlighted on page | Image credit: Feng Yu – stock.adobe.com

May 16th 2025

5 Ways the US Obesity Landscape Strays From the Global Picture

Hayden E. Klein

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial saturation, access, and long-term care distinct from other parts of the world.

$Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com$

May 16th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Courtney Flaherty

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions